Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alverine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | FDPS | P14324 | 1/20 | 0.62 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alverine SCHEMBL5061747 | 0.98 | KCNH2 (0.96) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL28961741 | 0.96 | KCNH2 (0.92) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Alverine SCHEMBL28064450 | 0.96 | KCNH2 (0.92) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL23677772 | 0.96 | KCNH2 (0.92) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL2791368 | 0.96 | KCNH2 (0.92) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Bromide SCHEMBL4266727 | 0.94 | KCNH2 (0.88) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL28770065 | 0.94 | KCNH2 (0.88) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Iodide SCHEMBL28601822 | 0.94 | KCNH2 (0.88) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL25183370 | 0.94 | KCNH2 (0.88) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL3278609 | 0.94 | KCNH2 (0.88) | KCNH2CHRM2HTR1AADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1721 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094666-A | Pharmaceutical composition comprising simethicone and alverine citrate, pharmaceutical composition comprising simethicone, pharmaceutical composition comprising alverine citrate and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| US-20260000645-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | ASS FRANCAISE CONTRE LES MYOPATHIES (FR) | 2026-01-01 | — | — | US | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| EP-4633618-A1 | TREATMENT OF TYPE 2 DIABETES AND/OR CHRONIC KIDNEY DISEASE WITH HEPATOCYTE NUCLEAR FACTOR 4 ALPHA (HNF4A) AGONISTS | Regeneron Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-12396990-B2 | Application of 5-hydroxytryptamine receptor 1A in preparing drug for portal hypertension | SECOND AFFILIATED HOSPITAL, SECOND MILITARY MEDICAL UNIVERSITY (CN) | 2025-08-26 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4551214-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | Association Française contre les Myopathies (FR) | 2025-05-14 | — | — | EP | claimed |
| US-12285488-B2 | Oral dosage form containing theobromine-free cocoa | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-04-29 | — | — | US | claimed |
| CN-115380021-B | Pharmaceutical composition for preventing or treating diseases associated with muscle weakness comprising alverine, 4-hydroxy alverine, derivatives thereof or pharmaceutically acceptable salts thereof | 安芃蒂公司 | 2025-04-08 | — | — | CN | claimed |
| US-20020028254-A1 | Manganese compositions for reducing/preventing skin wrinkles and fine lines | SOCIETE L'OREAL S.A. (FR) | 2002-03-07 | — | — | US | claimed |
| US-20020025345-A1 | Manganese compositions for treating skin vascular tissue and combating skin pallor | SOCIETE L'OREAL S.A. (FR) | 2002-02-28 | — | — | US | claimed |
| US-6335368-B1 | ADMINISTERING ALVERINE OR SALT COSMETIC TO SKIN AS MUSCLE RELAXANT; AGING RESISTANCE | SOCIETE L'OREAL S.A. (FR) | 2002-01-01 | — | — | US | claimed |
| EP-0830341-B1 | PROCESSES FOR THE PREPARATION OF 3-(METHYLTHIO)PROPANAL AND 2-HYDROXY-4-(METHYLTHIO)BUTANENITRILE | NOVUS INT INC (US) | 2001-09-05 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0830341-A1 | PROCESSES FOR THE PREPARATION OF 3-(METHYLTHIO)PROPANAL AND 2-HYDROXY-4-(METHYLTHIO)BUTANENITRILE | Novus International, Inc. (US) | 1998-03-25 | — | — | EP | claimed |
| US-5705675-A | REACTING METHYL MERCAPTAN WITH ACROLEIN USING BASIC CATALYST | NOVUS INTERNATIONAL, INC. (US) | 1998-01-06 | — | — | US | claimed |
| WO-1996040631-A1 | PROCESSES FOR THE PREPARATION OF 3-(METHYLTHIO)PROPANAL AND 2-HYDROXY-4-(METHYLTHIO)BUTANENITRILE | NOVUS INTERNATIONAL, INC. (US) | 1996-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | SMPD3, SMPD4, CMA1 | HTR1A 2484/4885KCNH2 1710/4885CHRM2 100/4885 |
| US-20260000645-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | ERAL1, MT-CO3, GFM1 | HTR1A 3692/4885KCNH2 2032/4885CHRM2 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.